Immune checkpoint therapy-current perspectives and future directions
10.1016/j.cell.2023.03.006 · 2023
Tumour-intrinsic resistance to immune checkpoint blockade
10.1038/s41577-019-0218-4 · 2020
Targeting the tumour vasculature: from vessel destruction to promotion
10.1038/s41568-024-00736-0 · 2024
Host tissue determinants of tumour immunity
10.1038/s41568-019-0125-9 · 2019
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
10.1126/scitranslmed.aak9679 · 2017
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy
10.1016/j.ccell.2022.01.002 · 2022
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop
10.1016/j.ccell.2022.12.006 · 2023
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
10.1073/pnas.1525349113 · 2016
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
10.1016/j.ccell.2023.04.010 · 2023
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
10.1126/scitranslmed.aak9670 · 2017
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
10.1056/nejmoa1915745 · 2020
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
10.1016/j.jhep.2021.11.030 · 2022
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells
10.1126/scitranslmed.3006504 · 2013
Mechanisms controlling PD-L1 expression in cancer
10.1016/j.molcel.2019.09.030 · 2019
Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes
10.1016/j.medj.2022.05.001 · 2022
Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene
10.1074/jbc.271.29.17247 · 1996
Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1
10.1128/iai.70.2.859-868.2002 · 2002
Paired-cell sequencing enables spatial gene expression mapping of liver endothelial cells
10.1038/nbt.4231 · 2018
Single-cell transcriptome atlas of murine endothelial cells
10.1016/j.cell.2020.01.015 · 2020
An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates
10.1016/j.ccell.2020.03.002 · 2020
Timed Ang2-targeted therapy identifies the Angiopoietin-Tie pathway as key regulator of fatal lymphogenous metastasis
10.1158/2159-8290.cd-20-0122 · 2021
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
10.1016/j.cell.2021.01.002 · 2021
Lipoprotein lipase: structure, function, regulation, and role in disease
10.1007/s00109-002-0384-9 · 2002
GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism
10.1016/j.cmet.2019.05.023 · 2019
Loss of myeloid lipoprotein lipase exacerbates adipose tissue fibrosis with collagen VI deposition and hyperlipidemia in leptin-deficient obese mice
10.1016/j.jbc.2022.102322 · 2022
ABCG1 orchestrates adipose tissue macrophage plasticity and insulin resistance in obesity by rewiring saturated fatty acid pools
10.1126/scitranslmed.adi6682 · 2024
Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer
10.1038/s41586-023-06733-x · 2023
Tumor endothelial cell-mediated antigen-specific T-cell suppression via the PD-1/PD-L1 pathway
10.1158/1541-7786.mcr-19-0897 · 2020
IFN-gamma-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis
10.1126/sciadv.abl5162 · 2022
Antigen recognition detains CD8+ T cells at the blood-brain barrier and contributes to its breakdown
10.1038/s41467-023-38703-2 · 2023
Lung endothelial cell antigen cross-presentation to CD8+ T cells drives malaria-associated lung injury
10.1038/s41467-019-12017-8 · 2019
Immunomodulation by endothelial cells - partnering up with the immune system
10.1038/s41577-022-00694-4 · 2022
Immunological functions of liver sinusoidal endothelial cells
10.1038/cmi.2016.5 · 2016
Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells
10.1084/jem.20142047 · 2015
T lymphocyte-endothelial Interactions: emerging understanding of trafficking and antigen-specific immunity
10.3389/fimmu.2015.00603 · 2015
Top 10 challenges in cancer immunotherapy
10.1016/j.immuni.2019.12.011 · 2020
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
10.1016/s2213-2600(19)30084-0 · 2019
Mechanisms of MHC-I downregulation and role in immunotherapy response
10.3389/fimmu.2022.844866 · 2022
Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy
10.1007/s00251-008-0303-5 · 2008
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
10.1038/s41591-022-01868-2 · 2022
